Stagnant sales for Bristol Myers Squibb’s Sotyktu have raised questions about whether the tyrosine kinase 2 (TYK2) inhibitor ...

Psoriatic arthritis (PsA) most often attacks and damages ... The more severe your PsA symptoms, the more likely you will have gum inflammation. Dental implants are part of the treatment for ...

(RTTNews) - Drug maker Bristol-Myers Squibb Co. (BMY) Monday announced positive topline results from two pivotal Phase 3 trials evaluating Sotyktu (deucravacitinib) in adults with active psoriatic ...

Bristol Myers on Monday said the two Phase 3 studies met their primary endpoint, with a significantly greater proportion of Sotyktu-treated patients achieving at least a 20% improvement in signs and ...

But lifestyle changes may reduce your chances of developing severe symptoms ... Common types of arthritis include osteoarthritis (OA), rheumatoid arthritis (RA), and psoriatic arthritis (PsA).

Long-term treatment with guselkumab is associated with sustained improvements in joint/skin symptoms and disease activity among patients with active PsA.

Differences in how men and women manifest and experience psoriatic arthritis suggest it’s time to think of patient sex as a ...

Topline data were announced from two phase 3 trials evaluating deucravacitinib, a tyrosine kinase 2 (TYK2) inhibitor, in adults with active psoriatic arthritis (PsA). POETYK PsA-1 (ClinicalTrials.gov ...

A study identifies clinical characteristics and predictors of psoriatic arthritis in patients with juvenile idiopathic ...

Across 2024, top immunology news focused on ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis, ...